It took until the fall of 2020 for Medicare to consistently pay an adequate amount for CAR-T therapy. Now that same agonizing process awaits a raft of promising gene therapies in the pipeline – with lives in the balance – unless policymakers take action.
Join Schaeffer Center Director Dana Goldman in conversation with Jeet Guram and Kathy Buto about policy lessons learned and potential solutions to support innovation and patient access in cell and gene therapies.
Out of the 1.3 million individuals between the ages of 50-79 who are diagnosed with cancer, only 15% of those cases will be caught early. Aspen Institute and USC Schaeffer Center partnered for an expert discussion on early detection technologies.